https://www.selleckchem.com/products/ml264.html
Cetuximab has been approved for use for first-line treatment of patients with wild-type KRAS metastatic colorectal cancer(CRC). However, treatment with cetuximab has shown limited efficacy as a CRC monotherapy. In addition, natural killer (NK) cell function is known to be severely attenuated in cancer patients. The goal of this study was to develop a new strategy to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) mediated by NK cells, in combination with cetuximab against CRC cells. Ex vivo expanded NK cells were stimulated w
Like
Comment
Share
